Vedamurthy A, Gangasani N, Ananthakrishnan, et al. - Researchers undertook this retrospective analysis to determine the effect of vedolizumab (VDZ) on the risk of new or recurrent cancers in inflammatory bowel disease patients with a previous malignancy. A total of 96 patients treated with VDZ following a prior diagnosis of cancer who were compared with 184 patients managed with tumor necrosis factor α antagonists (anti-TNF) and 183 with no immunosuppressive therapy were involved in this study. According to the findings, no increased risk of new or recurrent cancers was reported in relation to treatment with either vedolizumab or TNF-antagonists in patients with prior malignancy.